Merck Presents New Data on the Safety and Durable Efficacy of Cladribine Tablets and Advantages of Early Treatment with Rebif® at the 2016 ECTRIMS Congress - Seite 2

work that aims to improve the understanding of MS for the ultimate
benefit of patients. The symposium will take place in the South
Gallery 19 at the ExCel from 19:30-20:30 BST.

For more information about the data to be presented, please review
the ECTRIMS website (http://www.ectrims-congress.eu/2016.html). Also,
visit Merck's booth at this year's Congress to learn more about the
company's programs and commitment to advancing MS care.

About Cladribine Tablets

Cladribine Tablets is an oral small molecule prodrug that
selectively and periodically targets lymphocytes thought to be
integral to the pathological process of MS. Cladribine Tablets is
currently under clinical investigation and not approved for any use
in the United States, Canada and Europe.

About Rebif®

Rebif® (interferon beta-1a) is a disease-modifying drug used to
treat relapsing forms of multiple sclerosis (MS) and is similar to
the interferon beta protein produced by the human body. The efficacy
of Rebif® in chronic progressive MS has not been established.
Interferon ß is thought to help reduce inflammation. The exact
mechanism is unknown.

Rebif®, which was approved in Europe in 1998 and in the US in
2002, is registered in more than 90 countries worldwide. Rebif® has
been proven to delay the progression of disability, reduce the
frequency of relapses and reduce MRI lesion activity and area*.

Rebif® can be administrated with the RebiSmart® electronic
auto-injection device (not approved in the US), or with the RebiDose®
single-use disposable pen, or the manual multidose injection pen
RebiSlide(TM). Rebif® can also be administered with the autoinjector
Rebiject II® or by manual injection using ready-to-use pre-filled
syringes. These injection devices are not approved in all countries.

In January 2012, the European commission approved the extension of
the indication of Rebif® in early multiple sclerosis. The extension
of the indication of Rebif® has not been submitted in the United
States.

Rebif® should be used with caution in patients with a history of
depression, liver disease, thyroid abnormalities and seizures. Most
commonly reported side effects are flu-like symptoms, injection site
disorders, elevation of liver enzymes and blood cell abnormalities.
Patients, especially those with depression, seizure disorders, or
liver problems, should discuss treatment with Rebif® with their
doctors.

*The exact correlation between MRI findings and the current or
future clinical status of patients, including disability progression,
is unknown.

Rebif® (interferon beta-1a) is approved in the United States for